Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.

[1]  L. J. Rubinstein,et al.  Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny. , 1988, Journal of immunology.

[2]  Chung C. Hsu,et al.  Determining the optimum residual moisture in lyophilized protein pharmaceuticals. , 1992, Developments in biological standardization.

[3]  M. Pikal,et al.  Formulation and stability of freeze-dried proteins: effects of moisture and oxygen on the stability of freeze-dried formulations of human growth hormone. , 1992, Developments in biological standardization.

[4]  L. Bell,et al.  Thermally induced denaturation of lyophilized bovine somatotropin and lysozyme as impacted by moisture and excipients. , 1995, Journal of pharmaceutical sciences.

[5]  Tracy Chen,et al.  Thermal analysis of proteins of pharmaceutical interest , 1995 .

[6]  H Leuenberger,et al.  Effects of formulation and process variables on the aggregation of freeze-dried interleukin-6 (IL-6) after lyophilization and on storage. , 1998, Pharmaceutical development and technology.

[7]  M. Macka,et al.  The use of the Box-Behnken experimental design in the optimisation and robustness testing of a capillary electrophoresis method for the analysis of ethambutol hydrochloride in a pharmaceutical formulation. , 2002, Journal of pharmaceutical and biomedical analysis.

[8]  D. Brems,et al.  Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.

[9]  Chung C. Hsu,et al.  Effect of Moisture on the Stability of a Lyophilized Humanized Monoclonal Antibody Formulation , 2001, Pharmaceutical Research.

[10]  Xiaolin Tang,et al.  Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice , 2004, Pharmaceutical Research.

[11]  B. Chang,et al.  Development of an Efficient Single-Step Freeze-Drying Cycle for Protein Formulations , 1995, Pharmaceutical Research.

[12]  S. Duddu,et al.  The Relationship Between Protein Aggregation and Molecular Mobility Below the Glass Transition Temperature of Lyophilized Formulations Containing a Monoclonal Antibody , 1997, Pharmaceutical Research.

[13]  Kurt Brorson,et al.  Defining Your Product Profile and Maintaining Control Over It, Part 4 Product-Related Impurities: Tackling Aggregates , 2005 .

[14]  David Ouellette,et al.  Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? , 2005, Journal of pharmaceutical sciences.

[15]  Randall J Mrsny,et al.  Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.

[16]  Xudong Ge,et al.  Comparisons of optical pH and dissolved oxygen sensors with traditional electrochemical probes during mammalian cell culture , 2007, Biotechnology and bioengineering.

[17]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[18]  J. Carpenter,et al.  Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. , 2008, Journal of pharmaceutical sciences.

[19]  Xiaolin Tang,et al.  Evaluation of manometric temperature measurement, a process analytical technology tool for freeze-drying: Part I, product temperature measurement , 2006, AAPS PharmSciTech.

[20]  M. Manning,et al.  Impact of bulking agents on the stability of a lyophilized monoclonal antibody. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  M. Pikal,et al.  Development of freeze-dried biosynthetic Factor VIII: I. A case study in the optimization of formulation , 2009, Pharmaceutical development and technology.

[22]  T. Siahaan,et al.  Evaluation of the physical stability of the EC5 domain of E-cadherin: effects of pH, temperature, ionic strength, and disulfide bonds. , 2009, Journal of pharmaceutical sciences.

[23]  Linda O Narhi,et al.  High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.

[24]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[25]  Feng He,et al.  Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. , 2011, Journal of pharmaceutical sciences.